
With the Dividend Data connector, your AI app answers from the same data as this page and links the page behind each number. A free Dividend Data account connects.
Questions to try
HCM does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
Pro · $599/yr ($49/mo) · 30-day money-back guarantee
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Pro · $599/yr ($49/mo) · 30-day money-back guarantee
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses here and all seven in the Fair Value tool.
Pro unlocks it for HCM and 80,000+ other tickers.
Pro · $599/yr ($49/mo) · 30-day money-back guarantee
2 customers of HUTCHMED (China) Limited, named in SEC filings, company releases and earnings calls, with the quote behind each one, the share of revenue where a filing gives it, and how it moved.
Pro unlocks it for HCM and every other company we cover.
Pro · $599/yr ($49/mo) · 30-day money-back guarantee
See exactly how HCM's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab.
Pro · $599/yr ($49/mo) · 30-day money-back guarantee
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The company primarily addresses cancer and immunological disorders, serving a global patient population in addition to Hong Kong. Its operations are structured into two main segments: Oncology/Immunology and Other Ventures. The company boasts an extensive pipeline of drug candidates. Key assets include Savolitinib, an inhibitor developed for non-small cell lung…

— SYVIK ® becomes the first novel Syk inhibitor approved in China —

— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.

HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript

52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART-HCM fixed-dose oHCM Phase 2b and NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in first half of 2027 Cash, cash equivalents and investments of $503.5 million; cash runway expected into 2029 SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases, today reported unaudited financial results for the third quarter ended September 30, 2026, and provided a business update. “BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work,” said Travis Murdoch, M.D.